05:30 AM EST, 11/24/2025 (MT Newswires) -- Harbour BioMed said Monday that AstraZeneca ( AZN ) will continue adding new discovery projects to their partnership each year for the next four years, extending the collaboration that began in March 2025.

Harbour BioMed said it will have the option to license any of these projects for further development.

The company added that it could receive option fees, milestone payments, and tiered royalties on future sales, following the same financial terms established when the partnership was first formed.